272 related articles for article (PubMed ID: 22232276)
1. Determinants of quinolone versus trimethoprim-sulfamethoxazole use for outpatient urinary tract infection.
Stuck AK; Täuber MG; Schabel M; Lehmann T; Suter H; Mühlemann K
Antimicrob Agents Chemother; 2012 Mar; 56(3):1359-63. PubMed ID: 22232276
[TBL] [Abstract][Full Text] [Related]
2. Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections.
Gupta K; Hooton TM; Stamm WE
Ann Intern Med; 2001 Jul; 135(1):41-50. PubMed ID: 11434731
[TBL] [Abstract][Full Text] [Related]
3. Outcomes associated with trimethoprim/sulphamethoxazole (TMP/SMX) therapy in TMP/SMX resistant community-acquired UTI.
Gupta K; Stamm WE
Int J Antimicrob Agents; 2002 Jun; 19(6):554-6. PubMed ID: 12135847
[TBL] [Abstract][Full Text] [Related]
4. The current management strategies for community-acquired urinary tract infection.
Hooton TM
Infect Dis Clin North Am; 2003 Jun; 17(2):303-32. PubMed ID: 12848472
[TBL] [Abstract][Full Text] [Related]
5. Addressing antibiotic resistance.
Gupta K
Dis Mon; 2003 Feb; 49(2):99-110. PubMed ID: 12601340
[TBL] [Abstract][Full Text] [Related]
6. A Seven-Day Course of TMP-SMX May Be as Effective as a Seven-Day Course of Ciprofloxacin for the Treatment of Pyelonephritis.
Fox MT; Melia MT; Same RG; Conley AT; Tamma PD
Am J Med; 2017 Jul; 130(7):842-845. PubMed ID: 28216442
[TBL] [Abstract][Full Text] [Related]
7. Risk Factors for Trimethoprim and Sulfamethoxazole-Resistant Escherichia Coli in ED Patients with Urinary Tract Infections.
Wesolek JL; Wu JY; Smalley CM; Wang L; Campbell MJ
Am J Emerg Med; 2022 Jun; 56():178-182. PubMed ID: 35405469
[TBL] [Abstract][Full Text] [Related]
8. Fluoroquinolones in the treatment of acute uncomplicated urinary tract infections in adult women.
Garrison J; Hooton TM
Expert Opin Pharmacother; 2001 Aug; 2(8):1227-37. PubMed ID: 11584990
[TBL] [Abstract][Full Text] [Related]
9. Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens.
Raz R; Chazan B; Kennes Y; Colodner R; Rottensterich E; Dan M; Lavi I; Stamm W;
Clin Infect Dis; 2002 May; 34(9):1165-9. PubMed ID: 11941541
[TBL] [Abstract][Full Text] [Related]
10. Outpatient antibiogram and predictors of ciprofloxacin and trimethoprim-sulfamethoxazole resistant urinary tract infections.
Valentine-King M; Zoorob R; Grigoryan L; Trautner B
Ann Fam Med; 2022 Apr; 20(20 Suppl 1):. PubMed ID: 36944052
[TBL] [Abstract][Full Text] [Related]
11. Assessing adherence to evidence-based guidelines for the diagnosis and management of uncomplicated urinary tract infection.
Grover ML; Bracamonte JD; Kanodia AK; Bryan MJ; Donahue SP; Warner AM; Edwards FD; Weaver AL
Mayo Clin Proc; 2007 Feb; 82(2):181-5. PubMed ID: 17290725
[TBL] [Abstract][Full Text] [Related]
12. Trimethoprim-sulfamethoxazole resistance among urinary coliform isolates.
Wright SW; Wrenn KD; Haynes ML
J Gen Intern Med; 1999 Oct; 14(10):606-9. PubMed ID: 10571705
[TBL] [Abstract][Full Text] [Related]
13. Addressing antibiotic resistance.
Gupta K
Am J Med; 2002 Jul; 113 Suppl 1A():29S-34S. PubMed ID: 12113869
[TBL] [Abstract][Full Text] [Related]
14. The impact of trimethoprim-sulfamethoxazole as Pneumocystis jiroveci pneumonia prophylaxis on the occurrence of asymptomatic bacteriuria and urinary tract infections among renal allograft recipients: a retrospective before-after study.
Singh R; Bemelman FJ; Hodiamont CJ; Idu MM; Ten Berge IJ; Geerlings SE
BMC Infect Dis; 2016 Feb; 16():90. PubMed ID: 26912326
[TBL] [Abstract][Full Text] [Related]
15. The comeback of trimethoprim in France.
Caron F; Wehrle V; Etienne M
Med Mal Infect; 2017 Jun; 47(4):253-260. PubMed ID: 28043762
[TBL] [Abstract][Full Text] [Related]
16. Comparison of enoxacin versus trimethoprim-sulfamethoxazole in the treatment of patients with complicated urinary tract infection.
Gottlieb PL
Clin Ther; 1995; 17(3):493-502. PubMed ID: 7585853
[TBL] [Abstract][Full Text] [Related]
17. Antibiotic resistance in isolates recovered from women with community-acquired urinary tract infections presenting to a tertiary care emergency department.
Filiatrault L; McKay RM; Patrick DM; Roscoe DL; Quan G; Brubacher J; Collins KM
CJEM; 2012 Sep; 14(5):295-305. PubMed ID: 22967697
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility of the Index Urinary Tract Infection to Prophylactic Antibiotics Is a Predictive Factor of Breakthrough Urinary Tract Infection in Children with Primary Vesicoureteral Reflux Receiving Continuous Antibiotic Prophylaxis.
Lee JN; Byeon KH; Woo MJ; Baek HS; Cho MH; Jeong SY; Lee SM; Ham JY; Ha YS; Kim HT; Yoo ES; Kwon TG; Chung SK
J Korean Med Sci; 2019 Jun; 34(21):e156. PubMed ID: 31144480
[TBL] [Abstract][Full Text] [Related]
19. Uncomplicated urinary tract infections: lomefloxacin versus trimethoprim/sulphamethoxazole.
Guibert J; Capron MH
J Int Med Res; 1992 Nov; 20(6):467-74. PubMed ID: 1337525
[TBL] [Abstract][Full Text] [Related]
20. Randomized clinical trial of rifampin-trimethoprim and sulfamethoxazole-trimethoprim in the treatment of localized urinary tract infections.
Stein GE; Gurwith D; Gurwith M
Antimicrob Agents Chemother; 1988 Jun; 32(6):802-6. PubMed ID: 3046481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
